Physician profile

Mark J James

Emergency Medicine · Colorado Springs, CO

NPI 1275509390

$185.52

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$75.66

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Csl Behring $49.27 2019-2023 Kcentra
Bioxcel Therapeutics, INC. $26.04 2023 Igalmi
Medtronic, INC. $20.73 2024 Osteocool Rf Ablation System
Convatec INC. $18.09 2022
Pfizer INC. $15.94 2019
E.R. Squibb & Sons, L.L.C. $14.29 2021
Vapotherm INC $14.23 2022
Janssen Pharmaceuticals, INC $13.55 2020
Portola Pharmaceuticals, LLC $13.38 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Mark J James

$185.52

in general payments reported 2019-2025

Years
2019-2024
Top company
Csl Behring

https://glasscript.com/doctor/882774/mark-j-james

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.